Plus Therapeutics

Plus Therapeutics

Plus Therapeutics was founded in 2015 as a restructuring of Cytori Therapeutics, with Marc Hedrick, a plastic surgeon and veteran of the regenerative medicine sector, taking the helm as CEO. The company emerged from a reverse merger and a strategic pivot, shedding its prior focus on cell therapy to concentrate exclusively on oncology. It incorporates as a clinical-stage biotech rather than a traditional investment firm, but its function — allocating institutional capital, managing risk across a portfolio of drug candidates, and seeking regulatory milestones — mirrors that of a life-sciences asset manager operating its own pipeline. The firm's lead asset is Rhenium-186 NanoLiposome, a radiopharmaceutical designed to deliver targeted beta radiation directly into solid tumors via convection-enhanced delivery. Its therapeutic strategy focuses on recurrent glioblastoma, a uniformly fatal brain cancer with almost no durable treatment options, and leptomeningeal metastases, where cancer spreads to the cerebrospinal fluid. Plus Therapeutics secured a $17.6 million Product Development Research agreement with the Cancer Prevention and Research Institute of Texas in 2021 and expanded that support with a larger follow-on award of $33.1 million in 2024 (per the firm's public disclosures). The National Cancer Institute also enrolled the company's asset in its NExT Program to support manufacturing scale-up. The company operates out of Austin, Texas, and maintains clinical trial sites at major cancer centers including the University of Texas MD Anderson Cancer Center and the University of Texas Health Science Center at San Antonio. As a micro-cap public company trading on Nasdaq, its scale is limited — market capitalization ranged under $15 million through mid-2024 — with capital deployment governed by Phase 1 and Phase 2 clinical trial costs rather than an investment committee allocating to external managers. February 2024: Plus Therapeutics reported positive interim data from its ReSPECT-LM trial, showing a median overall survival of 11 months in patients with leptomeningeal metastases, a population that historically averages 2-5 months (per the firm's corporate presentation, 2024). Plus Therapeutics occupies a distinct niche: it is a single-asset clinical-stage biotech whose central technical insight is not a new molecule but a new use for an established isotope, repurposing a supply chain that already exists. Its structural differentiator is this regulatory and manufacturing pathway — seeking FDA approval by demonstrating safety and efficacy improvements in administration and targeting, rather than by inventing a novel compound. Succession risk is concentrated in Hedrick, who has served as CEO since the 2019 merger and personally shapes trial design and investor communication.